Electrochemotherapy of cholangiocellular carcinoma at hepatic hilum: a case report.
Eur Rev Med Pharmacol Sci
; 24(12): 7051-7057, 2020 06.
Article
en En
| MEDLINE
| ID: mdl-32633399
OBJECTIVE: Cholangiocarcinoma (CCA) is the second most common primary hepatic malignancy after hepatocellular carcinoma. The current standard palliative treatment, chemotherapy regimen with gemcitabine and cisplatin, prolongs overall survival only of a few months. Established locoregional therapies are not a curative option or an alternative to surgery in the treatment of CCA. We report a case of a patient affected by a cholangiocellular carcinoma at hepatic hilum treated by Electrochemotherapy (ECT) at our oncologic center. CASE PRESENTATION: A 71 years old male affected by a CCA at hepatic hilum was treated with ECT according to ESOPE guidelines. No complications occurred during ECT procedure. The patient was discharged after 10 days. The functional MR evaluation at 2 and at 4 months post-treatment showed a significant response without significant post-treatment adverse events. The Computed tomography (CT) assessment after 18 months did not show progression of disease. CONCLUSIONS: ECT is safe and its use could be suggested as a palliative treatment of advanced neoplastic lesions in which radical surgical treatment is not possible.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de los Conductos Biliares
/
Conductos Biliares Intrahepáticos
/
Cisplatino
/
Colangiocarcinoma
/
Desoxicitidina
/
Electroquimioterapia
/
Antineoplásicos
Tipo de estudio:
Guideline
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Eur Rev Med Pharmacol Sci
Asunto de la revista:
FARMACOLOGIA
/
TOXICOLOGIA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Italia
Pais de publicación:
Italia